Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT0594CP CAR-T Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
NCT05822037Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Apr 2023
- Primary completion
- Apr 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of CT0594CP in multiple myeloma (MM) and plasma cell leukemia (PCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Dose Limiting Toxicity. Started Apr 2023; status: recruiting.
02
Drugs
CT0594CP
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT05822037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822037.